Somatostatin receptor imaging, therapy and new strategies in patients withneuroendocrine tumours

Background: Somatostatin receptors have been found on a variety of neuroend ocrine tumours, such as carcinoids and paragangliomas, as well as on most p ancreatic endocrine and breast tumours. Somatostatin receptor scintigraphy with a radionuclide-labelled somatostatin analogue, [(111)Indium-diethylene triaminopenta-acetic acid]octreotide, is a sensitive and specific technique for visualizing in vivo the presence of somatostatin receptors on various tumours. Methods: Material was identified from previous review articles, references cited in original papers and a Medline search of the literature. Additional material was obtained from recently published abstracts of meetings. Results and conclusion: Somatostatin receptor imaging of neuroendocrine tum ours is essential in the diagnostic evaluation of most of these tumours. Th e expression of somatostatin receptors ia vivo not only predicts the outcom e of somatostatin analogue treatment but also opens the possibility of new therapeutic strategies. Because better information about spread of the dise ase can be obtained, more justiable options for therapy can be proposed.